- TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023
- Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the first quarter of 2024
- Expected cash runway extended through at least the second quarter of 2024 with recent $20 million in financing, with potential to receive up an additional $80 million
San Mateo, California, and Singapore, March 24, 2023 – ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.
Please refer to the press release in full.